Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Canine Idiopathic Epilepsy as a Natural Animal Model for Human Epilepsy: A Scoping Review Highlighting Metabolic Perspectives Beyond the Brain.

Nutrients·2026
Same author

Glofitamab monotherapy in patients with Richter transformation: safety and efficacy from a phase 1 study.

Blood advances·2026
Same author

Chronic Subthreshold Cortical Stimulation for Paracentral Epilepsy-A Systematic Review.

Neuromodulation : journal of the International Neuromodulation Society·2026
Same author

Palliative Care in Europe: Safeguarding Compassion Amidst Changing End-of-Life Policies and Expanding Access to Medically Assisted Dying Position Statement on behalf of the European Academy of Neurology, the European Federation of Neurological Associations and OneNeurology.

European journal of neurology·2026
Same author

Patient-specific alterations in blood plasma cfRNA profiles enable accurate classification of cancer patients and controls.

Communications medicine·2026
Same author

Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial.

Haematologica·2026
Same journal

Synergistic pain relief in cervical radiculopathy: A randomized trial of topical methylcobalamin gel with phonophoresis and Mulligan mobilization.

Acta neurologica Belgica·2026
Same journal

Characterizing cranial tremors in a case of spinocerebellar ataxia type 12: a unique positional tremor.

Acta neurologica Belgica·2026
Same journal

A case of coexistence of spinal intradural capillary hemangioma and craniocervical junction dural arteriovenous fistula.

Acta neurologica Belgica·2026
Same journal

Comment on "Content quality and reliability of youtube exercise videos for parkinson's disease".

Acta neurologica Belgica·2026
Same journal

A novel CHMP2B variant of uncertain significance in a patient with apathy, hyperorality, and mild language impairment.

Acta neurologica Belgica·2026
Same journal

Photon-counting CT-angiography in comparison to digital subtraction angiography and MR-angiography for assessing intra-aneurysmal flow disrupting devices.

Acta neurologica Belgica·2026
See all related articles

Related Experiment Video

Updated: Jul 5, 2026

Sampling Cerebrospinal Fluid and Blood from Lateral Tail Vein in Rats During EEG Recordings
10:46

Sampling Cerebrospinal Fluid and Blood from Lateral Tail Vein in Rats During EEG Recordings

Published on: September 1, 2023

Levetiracetam and bleeding disorders.

Paul Boon1, Réginald Hulhoven, Fritz Offner

  • 1Department of Neurology, Reference Center for Refractory Epilepsy, Ghent University Hospital, Belgium. Paul.Boon@UGent.be

Acta Neurologica Belgica
|April 18, 2008
PubMed
Summary
This summary is machine-generated.

Levetiracetam (an anti-seizure medication) did not cause clinically significant increases in bleeding time in healthy men, even when taken with aspirin. Hematological adverse events were also not observed.

Related Experiment Videos

Last Updated: Jul 5, 2026

Sampling Cerebrospinal Fluid and Blood from Lateral Tail Vein in Rats During EEG Recordings
10:46

Sampling Cerebrospinal Fluid and Blood from Lateral Tail Vein in Rats During EEG Recordings

Published on: September 1, 2023

Area of Science:

  • Pharmacology
  • Clinical Trials
  • Hematology

Background:

  • Levetiracetam is an anti-epileptic drug.
  • Potential interactions between levetiracetam and drugs affecting bleeding, such as aspirin, require investigation.

Purpose of the Study:

  • To evaluate the effect of levetiracetam on bleeding time in healthy male volunteers.
  • To assess the clinical relevance of any observed changes in bleeding time.

Main Methods:

  • Six studies were conducted in healthy male volunteers.
  • Included open-label and double-blind, placebo-controlled crossover designs.
  • Levetiracetam was administered at various doses, alone and in combination with acetylsalicylic acid (aspirin).

Main Results:

  • Minor increases in bleeding time were observed in some studies, but these were not dose-related and not clinically relevant.
  • No clinically significant difference in bleeding time compared to placebo was found in double-blind studies.
  • No clinically significant hematological adverse events were identified in a review of clinical trials.

Conclusions:

  • Levetiracetam does not produce clinically significant increases in bleeding time in healthy male volunteers.
  • Levetiracetam does not appear to cause clinically significant hematological adverse events.